**Core Concept**
ADAMTS-13 is a metalloprotease enzyme responsible for cleaving and regulating von Willebrand factor (VWF), a key protein involved in blood coagulation. Its deficiency or inhibition can lead to excessive VWF activity, resulting in thrombotic microangiopathy (TMA).

**Why the Correct Answer is Right**
ADAMTS-13 deficiency is a known cause of Thrombotic Thrombocytopenic Purpura (TTP), a rare blood disorder characterized by the formation of blood clots in small blood vessels throughout the body. This occurs due to the accumulation of ultra-large VWF multimers, which are highly adhesive and lead to platelet activation and aggregation. Inhibition of ADAMTS-13 by autoantibodies is another mechanism contributing to TTP.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is not relevant to the question. While coagulation disorders are a broad category, they encompass many conditions unrelated to ADAMTS-13 deficiency.

**Option B:** This option is incorrect because ADAMTS-13 deficiency is not typically associated with disseminated intravascular coagulation (DIC). DIC is characterized by widespread clotting and bleeding, often due to an underlying condition such as sepsis or trauma.

**Option C:** This option is incorrect because von Willebrand disease (VWD) is a bleeding disorder caused by a deficiency or dysfunction of VWF, not ADAMTS-13.

**Clinical Pearl / High-Yield Fact**
ADAMTS-13 deficiency is a key differential diagnosis for patients presenting with microangiopathic hemolytic anemia, thrombocytopenia, and renal failure, particularly in the absence of other identifiable causes.

**Correct Answer: C. Thrombotic Thrombocytopenic Purpura (TTP)**